ReviewFrontiers in cell and developmental biology2025
Role of histone post-translational modifications in atherosclerosis and the therapeutic potential of targeting epigenetic modifiers.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mechanotransduction Failure and Molecular Rescue in Gastric Cancer: Kinetotherapy Across the IL-6/STAT3-Myostatin/ACVR2B-Akt/mTOR Axis.Medical sciences (Basel, Switzerland) · 2026Review
- Environmental Exposure to Micro- and Nanoplastics: Linking Cardiovascular Disease and Cancer Through Shared Biological Pathways-A Critical Review.Antioxidants (Basel, Switzerland) · 2026Review
- Per- and Polyfluoroalkyl Substances Exposure and Ischemic Heart Disease: Emerging Evidence from the Literature.Antioxidants (Basel, Switzerland) · 2026Review
- Endothelial FOXO1 Lactylation: A New Link Between Disturbed Flow and Atherosclerosis.Circulation research · 2026Article
- The lactate-lactylation axis in tumor radioresistance: metabolic, epigenetic, and immune mechanisms with emerging links to RNA regulation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with atherosclerosis being the primary pathological substrate underlying most CVD. Epigenetics, defined as a set of regulatory mechanisms that dynamically modulate gene expression patterns or protein functional states through chemical modifications without altering the primary sequence of the genome, has been increasingly recognized as a pivotal driver in the pathogenesis of various diseases. Histone post-translational modifications, such as acetylation, methylation and lactylation, are catalyzed by specific enzymes and are essential for the regulation of gene expression, which in turn influences cellular functions and the progression of diseases. Notably, dysregulation of specific histone modifications is closely associated with the onset and progression of cardiovascular disorders. Accumulating evidence has demonstrated that aberrant histone modifications disrupt vascular cell homeostasis and contribute to atherogenesis by shaping the transcriptional landscape of vascular cells. On the one hand, histone modifications directly influence cellular functions (e.g., endothelial barrier integrity, macrophage lipid phagocytosis, and vascular smooth muscle cell phenotypic switching) and thereby drive atherosclerotic progression. On the other hand, these epigenetic modifications are dynamically modulated by major atherogenic risk factors, including dyslipidemia, pro-inflammatory cytokine release, and hemodynamic stimulation. This review focuses on the multifaceted roles of histone post-translational modifications in mediating vascular dysfunction during atherosclerosis, with an emphasis on the molecular mechanisms linking specific modifications to pathological cellular behaviors. Additionally, we highlight emerging therapeutic strategies targeting histone modification pathways, with the goal of advancing the development of precision diagnostics and interventions for atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.